For a 1.6 cm adrenal mass, what are the guidelines for surgical evaluation?

Management of a 1.6 cm Adrenal Mass

A 1.6 cm adrenal mass does NOT require surgical evaluation based on size alone, but DOES require complete hormonal workup and appropriate imaging characterization to determine if it is a benign, non-functional adenoma that can be safely observed. 1

Initial Evaluation Algorithm

Step 1: Imaging Characterization

• Obtain non-contrast CT if not already done to measure Hounsfield Units (HU) 1
  • If HU ≤10: This indicates a lipid-rich benign adenoma with near-zero malignancy risk 1
  • If HU >10: Proceed to second-line imaging (washout CT or chemical shift MRI) 1

Critical caveat: At 1.6 cm, malignancy risk is extremely low. Most surgically resected pheochromocytomas and adrenocortical carcinomas are >4 cm at diagnosis 1. However, size alone cannot exclude functional tumors.

Step 2: Mandatory Hormonal Workup

All patients require screening for hormone excess regardless of size 1:

1. Autonomous cortisol secretion (all patients):

   • 1 mg overnight dexamethasone suppression test 1, 2
   • Cortisol >50 nmol/L (>1.8 µg/dL) indicates mild autonomous cortisol secretion (MACS)

2. Pheochromocytoma screening:

   • Skip if: HU <10 on CT AND no signs/symptoms of catecholamine excess 1
   • Required if: HU >10 OR any symptoms (hypertension, palpitations, headaches, sweating) 1
   • Test: Plasma or 24-hour urinary fractionated metanephrines 1, 2

3. Primary aldosteronism (only if hypertensive or hypokalemic):

   • Aldosterone-to-renin ratio 1

4. Androgen excess (only if virilization signs present):

   • Serum DHEA-S, testosterone 1

Surgical Indications for 1.6 cm Mass

Surgery is indicated ONLY if:

• Functional tumor identified: Pheochromocytoma, aldosterone-secreting adenoma, or overt Cushing's syndrome 1, 3
• MACS with progressive metabolic comorbidities in younger patients after shared decision-making 1
• Indeterminate imaging (cannot characterize as benign) after second-line imaging - requires shared decision-making 1, 4

Surgery is NOT indicated if:

• Benign imaging features (HU <10) AND non-functional 1
• Size <4 cm with benign characteristics 1, 2

Follow-Up Protocol for Non-Surgical Masses

If benign-appearing (HU <10) and non-functional at 1.6 cm:

• No further imaging or hormonal testing required 1
• This is a strong recommendation with moderate quality evidence 1

If indeterminate but non-functional:

• Repeat imaging at 3-6 months, then annually for 1-2 years 2, 4
• Repeat hormonal testing annually for up to 5 years 2
• Consider surgery if: Growth >5 mm/year after repeating functional workup 1
• No further follow-up needed if: Growth <3 mm/year 1

Special Populations Requiring Expedited Evaluation

Higher suspicion for malignancy in 1:

• Young adults and children
• Pregnant patients
• Patients with known extra-adrenal malignancy

These patients should be discussed in multidisciplinary tumor board even at smaller sizes 1.

Common Pitfalls to Avoid

1. Do not skip pheochromocytoma screening before any biopsy or surgery - this can cause hypertensive crisis and death 1, 4

2. Do not assume size <4 cm excludes functional tumors - pheochromocytomas and hormone-secreting adenomas can be small 1

3. Do not rely on contrast-enhanced CT alone - approximately 1/3 of pheochromocytomas can show adenoma-like washout patterns, and 1/3 of adenomas may not wash out appropriately 1

4. Do not perform routine biopsy - it is rarely indicated and contraindicated if pheochromocytoma not excluded 1

5. Beware of bilateral masses - each requires separate characterization; consider congenital adrenal hyperplasia and adrenal insufficiency in infiltrative disease 1